Under DoH's managed entry policy, an innovative drug's Abu Dhabi revenue can depend on a confidential agreement and on patient outcomes. A valuation built on list price will miss both.

The cover applies the policy to DoH-licensed providers, DoH-authorised payers and all health insurance products as applicable, which reads as if every Abu Dhabi insurer could strike these deals. The definitions narrow it. The payer, for the purpose of the policy, is DoH acting through its appointed third-party administrator, and the roles table names the National Health Insurance Company as that administrator.

The scope section applies the policy to products used by Thiqa, Basic and ABM members. The agreement is signed by the regulator, the payer and the manufacturer. A private insurer writing enhanced plans is not a party, and on our reading a manufacturer's commercial terms with those insurers sit outside the policy.

The policy recognises two families. Financial agreements have the manufacturer contribute to cost without reference to outcomes: discounts, price-volume agreements, manufacturer-funded diagnostics or initial treatment, free doses and dose caps. The policy gives hepatitis C as a population-level example suited to a budget cap, and immunotherapies with variable dosing as a patient-level one. Outcome-based agreements tie payment to clinical results, through conditional coverage while data are collected or through reimbursement calculated against pre-agreed measures.

The policy lists four standard outcome types: survival; disease progression, relapse or recurrence; long-term side effects; and return to normal activities. Candidates are products of high cost or unmet need, especially those with small patient populations, immature trial data or outcomes measurable in the short term. DoH may identify medicines still under registration review in the UAE, and manufacturers may propose agreements themselves.

Three provisions decide how a buyer reads Abu Dhabi revenue. Confidentiality is required. The agreements are expressly not for purchase of medications; procurement runs through other entities, which the roles table identifies as the government-sector unified procurement company.

And all data belong to DoH: the manufacturer has no access to confidential patient data, and audit can be carried out by a hired third party. The supply contract and the price a distributor reports can therefore sit apart from a rebate, a cap or an outcome adjustment that changes what the product actually earns, and in an outcome-based deal the manufacturer cannot independently check the data that set its payment.

The policy's own success measures are the number of agreements on high-spend drugs and the reduction in pharmaceutical spend for Thiqa, Basic and ABM. DoH states in the text that the aim is to pay less for these products.

For anyone valuing a drug licence, a specialty distributor's portfolio or a pharma company's Abu Dhabi business, list price multiplied by forecast volume is now an upper bound for any product under an agreement. Each agreement must also contain sections on assignments and subcontracting, termination and liability, is governed by UAE federal law, and gives the Abu Dhabi courts exclusive jurisdiction.

On our reading, whether an agreement follows a product to a new licence holder or distributor depends on that assignment clause, and a change of rights holder without it could reopen coverage. Saudi Arabia's MOH has run its own managed entry policy since January 2021, with procurement through NUPCO, so a GCC launch plan can face two confidential net prices under two regimes (Saudi MOH Managed Entry Agreement Policy, AST.SM-010-CPP).

The text describes a pilot on a small number of products, with medical devices possibly added later. It publishes no list of agreements, no price benchmark for "high cost" and no timeline for DoH's decision. Whether a product is covered under an agreement is therefore something a buyer learns from the seller, and should verify with the counterparties.